Hera Biotech Announces Positive Interim Results From Endometriosis Dia...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 3, 2024

Government of Canada and the Government of Manitoba announce partnership to develop a Red Dress Alert together with Indigenous p • University of Phoenix College of Nursing Alumna and Faculty Publish Article on Lived Experiences of Intensive Care Unit Nursing • California Launches Youth-Focused Statewide Adverse Childhood Experiences (ACES) Campaign • Northern Trust Named Best Private Bank in U.S. for Digital Wealth Planning, Best Digital Innovator of the Year in U.S. • Lac Seul First Nation and Canada settle Flooding Claim • Brown Books Kids Publishes Children’s Picture Book, Perfect for Summer Reading • i3 Verticals Announces Earnings Release and Conference Call Date for Second Quarter of Fiscal 2024 • Governments of Canada, Saskatchewan and Prince Albert Grand Council announce funding to study implementation of Indigenous-led p • Innovative partnership to bring 100 units of social and affordable housing units for independent seniors to Terrebonne • Water Engineering Inc., a Portfolio Company of Nolan Capital, Announces the Acquisition of WET Solutions, Inc., a Leading Provid • High School Women Launch First of its Kind Energy Literacy Podcast • Melmark's Dream Maker's Ball Raised $500,000 to Support Individuals with Intellectual and Developmental Disabilities • Tennant Company Announces Senior Leadership Updates to Direct ERP Transformation and Drive Product Innovation • Valley Children's Receives Historic $15 Million Gift to Create Advanced Cell Therapy Program for Pediatric Cancer • CORRECTING and REPLACING Wheaties™ Pushes the Limits of Breakfast with New Wheaties Protein • AHF Backs FTC Challenge to Big Pharma Junk Patents • The Iconic Caribbean Posh Weekend Returns To The USVI; Will Honor Dr. Yvette Noel-Schure • ZACAPA RUM AND RAUL LOPEZ OF LUAR UNVEIL A LIMITED-EDITION COLLECTION: AN ODE TO HERITAGE, COMMUNITY, AND CRAFTSMANSHIP • WWPR WELCOMES RETURNING MEMBERS TO 2024 - 2025 ADVISORY COUNCIL • REAL SALT LAKE AND ALSCO UNIFORMS EXTEND PARTNERSHIP TO INCLUDE UTAH ROYALS

Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Study

SAN ANTONIO , April 23 /Businesswire/ - Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test. Per protocol data from the first 38 patients who have been enrolled in the 60 patient study shows that the diagnostic test is performing with 92% sensitivity, 95% specificity and an overall accuracy (AUC) of 94%, as compared to the histopathology of excised lesions.

“This result suggests that Hera’s molecular diagnostic test has the potential to replace surgical diagnosis and greatly improve the woefully inadequate state of endometriosis diagnosis and treatment that exists today,” said Hera Biotech CEO Somer Baburek.

Hera is focused on a tissue based approach for diagnosing endometriosis, utilizing a pipelle to non-surgically obtain endometrial cells for analysis. Multiple genes are analyzed in numerous cells from each patient, which provides thousands of data points for analysis using a proprietary AI generated algorithm. This single cell assay complements the bulk Polymerase Chain Reactions (PCR) assay it acquired from Scailyte earlier this year. Based on these promising results, Hera intends to bring a rapid bulk PCR endometriosis diagnostic test to market in 2025.

“In addition to providing a definitive diagnosis, the results from this interim analysis also shows robust accuracy in staging the disease between early and late stages, a critical determinant in assisting the physician plan treatment options for the patient,” said Hera Biotech COO Dr. Cinzia Donato. “The ability to stage disease is currently not available until after the patient is in surgery, as there is no reliable correlation between disease symptoms and disease severity. Furthermore, the ability to non-surgically diagnose early disease opens up the possibility to screen young patients before the disease has had years to develop and intervene much earlier than currently possible.”

Hera plans to complete the study and announce final results mid-year. To commercialize the tests under development, the company is currently raising a Series A round of finance.

About Hera Biotech

Hera Biotech was formed to apply advances in biotechnology to address unmet needs in women’s healthcare. Its lead product is MetriDx™, a novel, non-surgical test that utilizes gene expression analysis of proprietary biomarkers in endometrial cells for the definitive, early diagnosis and staging of endometriosis.

Hera Biotech was founded in 2020 by Somer Baburek (CEO), Dr. Paul Castella (Executive Chairman), Dr. Bruce Nicholson (CSO), and Dr. Nameer Kirma (Chair of Advisory Board). A bi-product of combined fields of expertise, Hera Biotech is changing the women’s health landscape with its potentially life-changing test for early diagnosis and staging of endometriosis.

For more information, please visit herabiotech.com. Find our link to the media kit here: https://drive.google.com/drive/folders/1LtROaOB-q7cr3mSzVD1uz92XRiavfxL9?usp=sharing

About Endometriosis

Endometriosis can be an extremely painful disorder in which tissue that normally lines the uterus migrates and grows on other organs outside of the uterus. It affects roughly 10-20% of women worldwide and contributes to a large majority of female infertility cases. There is no rapid test for endometriosis, a highly prevalent and debilitating disease, and the current standard of diagnosis is an expensive surgical procedure with histopathology of the excised lesions.

Hera Co-Founders, and co-inventors of the technology, Drs. Bruce Nicholson and Nameer Kirma have been working for many years at the University of Texas Health Science Center San Antonio on the microfluidic, single cell gene analysis technology behind MetriDx™. The University of Texas Health Science Center San Antonio is also one of the centers conducting the multi-center clinical trial. Hera will offer MetriDx™ to both OB/GYN practices and the fertility solutions market to enable the detection and diagnosis of endometriosis without surgery. Furthermore, Hera believes MetriDX™ will help drive the development of new therapeutics for endometriosis, which is currently stymied in the clinic by need for surgical diagnosis and monitoring. Changing the diagnostic landscape for those suffering from this extremely painful condition is potentially life changing. MetriDx™ is a non-surgical solution for diagnosis that Hera hopes to provide endo patients worldwide and help profoundly reshape women’s healthcare options.